University System of Maryland

Regeneron Pharmaceuticals, Inc.

Regeneran Pharmaceuticals, Inc.

Da-Wei Gong

Alan R Shuldiner

Cristopher Van Hout

Nehal Gosalia

Rongze Yang

James A Perry

John C McLenithan

Rong-Ze Yang

Daozhan Yu

Alan Shuldiner

Ling Chen

The present disclosure provides methods of treating patients having decreased bone mineral density, methods of identifying subjects having increased risk of developing decreased bone mineral density, methods of detecting human Zinc And Ring Finger 3 (ZNRF3) variant nucleic acid molecules and variant polypeptides, and ZNRF3 variant nucleic acid molecules and variant polypeptides.

Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors

The present disclosure provides methods of treating subjects having increased lipid levels, methods of identifying subjects having an increased risk of developing an increased lipid level, methods of detecting human Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) variant nucleic acid molecules and variant polypeptides, and SREBF1 variant nucleic acid molecules and variant polypeptides.

Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors

The present disclosure provides methods of treating subjects having increased lipid levels and/or increased triglyceride levels, methods of identifying subjects having an increased risk of developing an increased lipid level and/or increased triglyceride level, methods of detecting human Sterol Regulatory Element Binding Protein Cleavage-Activating Protein (SCAP) variant nucleic acid molecules and variant polypeptides, and SCAP variant nucleic acid molecules and variant polypeptides.

Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (SCAP) inhibitors

The present invention generally to methods of treating subjects suffering from a cardiac condition or having a risk factor for developing a cardiac condition by administering an ELA peptide or fusion protein to a subject in need. The invention relates to fusion proteins of Fc-ELA-32 and Fc-ELA-21 that exhibit improved properties for use as therapeutic agents, e.g. in the treatment of cardiac conditions. In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.

Methods for treating cardiovascular dysfunction and improving fluid homeostasis with Elabela peptide hormone

The present invention is directed to methods of diagnosing a disease or predicting an increased risk of a disease, such as obesity, obesity-dependent subacute inflammation, atherosclerosis, cardiovascular disease and a metabolic disease, by determining the levels of omentin 1 and 2 protein in a subject, or by determining the levels of omentin 1 and 2 gene expression in a subject. The present invention is also directed to methods of disease treatment using omentin 1 protein and omentin 2 protein.

Method of diagnosing or predicting disease states in a subject using omentin 1 and omentin 2

Novel alanine transaminase (ALT) polypeptides and the use thereof as a diagnostic marker to predict and monitor tissue damage and/or tissue malfunction. The ALT polypeptides are murine and/orALT polypeptides and said ALT polypeptides are used to detect, predict and/or determine hepatic processes of an animal, particularly mice and/or rats.

Alanine transaminase enzymes and methods of use

Isolated omentin polypeptides that selectively express in omental fat tissue and methods for the use of the polypeptides. The polypeptides can be used in a method for modifying insulin action and/or glucose metabolism in an animal. The polypeptides can be used to promote glucose uptake by animal adipocytes and other cells, tissues, and/or organs. The polypeptides can also used to provide a therapeutic treatment for diseases of or related to glucose metabolism and adipose tissues. The polypeptides are also incorporated into diagnostic tests and testing kits for diagnosing or detecting a disease or condition involving animal tissue that contains, uses, or expresses the polypeptide in an animal suspected of having the disease or condition.

Growing community of inventors

Olney, MD, United States of America

Da-Wei Gong